...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
【24h】

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents

机译：用于治疗多发性骨髓瘤的新型剂：蛋白酶体抑制剂和免疫调节剂

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The integration of novel agents into the treatment of multiple myeloma (MM) has shifted the focus from an incurable disease to one that is chronic, with a realistic hope of someday achieving a cure. Proteasome inhibitors and immunomodulatory agents are the backbone of novel therapies for MM. These agents are particularly important for patients with relapsed or refractory disease, a fate faced by the majority of myeloma patients over the course of their disease. Review of recent clinical trial data for the proteasome inhibitors and immunomodulatory agents, including clinical efficacy and safety information, will assist the advanced practitioner in oncology with integrating these data into the current treatment guidelines for MM.
机译：新型剂的整合到多发性骨髓瘤（mm）的治疗中已将焦点从不可治区的疾病转移到慢性，有一天达到治愈的实际希望。 蛋白酶体抑制剂和免疫调节剂是MM的新疗法的骨架。 这些试剂对复发或难治性疾病的患者尤为重要，这是大多数骨髓瘤患者面临的命运，在其疾病过程中。 回顾近期蛋白酶体抑制剂和免疫调节剂的临床试验数据，包括临床疗效和安全信息，将协助肿瘤学中的先进从业者将这些数据集成到目前MM的当前治疗指南中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号